[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336303-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336303-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","mixed-adenosquamous-cell-carcinoma-of-the-prostate-with-paired-sequencing-on-the-primary-and-liver-metastasis","Mixed Adenosquamous Cell Carcinoma of the Prostate with Paired Sequencing on the Primary and Liver Metastasis","","This case report examines diagnostic and treatment challenges in mixed adenosquamous cell carcinoma of the prostate, an uncommon prostate cancer variant with complex histology. A 63-year-old man with metastatic disease received multimodal therapy, starting with carboplatin, docetaxel, and androgen deprivation, then androgen receptor pathway inhibitor maintenance. Progression required radiation and a treatment change to Lutetium-177 vipivotide tetraxetan after chemotherapy difficulties. Paired genomic profiling showed shared mutations between prostate and liver lesions, supporting targeted therapeutic choices. PSMA-targeted therapy produced a notable PSA decline, illustrating integration of genomic insights into tailored management.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mixed-adenosquamous-cell-carcinoma-of-the-prostate-with-paired-sequencing-on-the-primary-and-liver-metastasis/336303/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mixed-adenosquamous-cell-carcinoma-of-the-prostate-with-paired-sequencing-on-the-primary-and-liver-metastasis/336303.png","ImageObject",300,407,{"name":42,"@type":43},"Ivy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main focus of this case report?","Question",{"text":63,"@type":64},"The report focuses on the diagnosis and treatment challenges of mixed adenosquamous cell carcinoma of the prostate, including how paired sequencing informs management.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What treatments were used for the patient in this case?",{"text":68,"@type":64},"The patient received carboplatin, docetaxel, and androgen deprivation therapy, followed by androgen receptor pathway inhibitor maintenance; later, radiation was given and therapy switched to Lutetium-177 vipivotide tetraxetan after chemotherapy challenges.",{"name":70,"@type":61,"acceptedAnswer":71},"What did genetic profiling reveal and how did it affect treatment?",{"text":72,"@type":64},"Comprehensive profiling showed shared mutations between prostate and liver lesions, supporting targeted therapy decisions. PSMA-targeted therapy led to a notable PSA decline.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336303,1790146497,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":107,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","Case Report  \nMixed Adenosquamous Cell Carcinoma of the Prostate with Paired Sequencing on the Primary and Liver Metastasis  \nEmmanuella Oyogoa 1,*, Maya Sonpatki 2, Brian T. Brinkerhoff 3, Nicole Andeen 3, Haley Meyer 4, Christopher Ryan 3 and Alexandra O. Sokolova 5  \nCitation: Oyogoa, E.; Sonpatki, M.; Brinkerhoff, B.T.; Andeen, N.; Meyer, H.; Ryan, C.; Sokolova, A.O. Mixed Adenosquamous Cell Carcinoma of the Prostate with Paired Sequencing on the Primary and Liver Metastasis. Curr. Oncol. 2024, 31, 2393–2399 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)curroncol31050178  \nReceived: 15 February 2024  \nRevised: 18 March 2024  \nAccepted: 21 March 2024  \nPublished: 24 April 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA  \n2 Department of Microbiology, Oregon State University, Corvallis, OR 97331, USA  \n3 Department of Pathology and Laboratory Medicine, Oregon Health and Science University, Portland, OR 97239, USA  \n4 Department of Internal Medicine, Mayo Clinic, Rochester, MN 55902, USA  \n5 Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Sciences University, Portland, OR 97239, USA  \n* Correspondence: [oyogoa@ohsu.edu](oyogoa@ohsu.edu)  \nAbstract: This report aims to shed light on the intricate challenges encountered during the diagnosis and treatment of an uncommon variant of prostate cancer—mixed adenosquamous cell carcinoma of the prostate. Prostate cancers of this nature pose distinctive diagnostic and therapeutic dilemmas due to their rarity and complex histological composition. We present a case of a 63-year-oldman with metastatic prostate cancer, featuring adenocarcinoma with squamous cell differentiation, who underwent a multimodal treatment approach. The patient responded to first-line carboplatin, docetaxel, and androgen deprivation therapy, followed by androgen receptor pathway inhibitor (ARPI) maintenance. However, disease progression led to radiation therapy and a subsequent switch to Lutetium (177Lu) vipivotide tetraxetan after chemotherapy challenges. Comprehensive genetic profiling revealed shared mutations in the prostate and liver lesions, emphasizing the role of targeted therapies. Prostate-specific membrane antigen (PSMA)-targeted therapy resulted in a notable PSA decline. This case highlights the evolving treatment landscape for rare prostate cancers, integrating genetic insights for tailored interventions. In conclusion, squamous cell carcinoma (SCC) of the prostate is rare, emphasizing the imperative for enhanced comprehension in diagnosis and management. Our case suggests the potential efficacy of ARPI and PSMA-targeted therapies. Our findings advocate fora more nuanced approach to the management of this rare prostate cancer variant, leveraging genomic insights for personalized treatment strategies. This exploration serves as a foundation for further research and clinical considerations in addressing the challenges posed by mixed adenosquamous cell carcinoma of the prostate.  \nKeywords: squamous cell carcinoma of the prostate; mixed adenosquamous cell carcinoma of the prostate; prostate cancer; prostate-specific membrane antigen positron emission tomography (PSMA PET)  \n1. Introduction  \nProstate cancer stands as the most prevalent non-cutaneous malignancy among American men [1], with an estimated 288,300 new cases in 2023 [2] . Adenocarcinoma constitutes 95% of prostate cancer cases, representing the predominant histology. Conversely, squamous cell carcinoma (SCC) of the prostate is a rare manifestation accounting for less th","cbCaiirvKZYZwzCn","https://ap.wps.com/l/cbCaiirvKZYZwzCn","pdf",1099517,"English","# Abstract\n# Introduction\n# Case Report","[{\"question\":\"What is the main focus of this case report?\",\"answer\":\"The report focuses on the diagnosis and treatment challenges of mixed adenosquamous cell carcinoma of the prostate, including how paired sequencing informs management.\"},{\"question\":\"What treatments were used for the patient in this case?\",\"answer\":\"The patient received carboplatin, docetaxel, and androgen deprivation therapy, followed by androgen receptor pathway inhibitor maintenance; later, radiation was given and therapy switched to Lutetium-177 vipivotide tetraxetan after chemotherapy challenges.\"},{\"question\":\"What did genetic profiling reveal and how did it affect treatment?\",\"answer\":\"Comprehensive profiling showed shared mutations between prostate and liver lesions, supporting targeted therapy decisions. PSMA-targeted therapy led to a notable PSA decline.\"}]","Mixed Adenosquamous Cell Carcinoma of the Prostate with Paired Sequencing on the Primary and Liver Metastasis | PDF",1790014475,18,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c99ac16f41d20ab5ed7d7f55b9f7a40.webp",983,1390,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4605c3b4eece89a461cad3deceabf72c.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8167f963a077d64fe6bb06fade5baed5.webp",981,1387,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c19c80756bfa6ecc8577c882d2eab383.webp",980,1385]